Martin H. Voss
About
Martin H. Voss is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Cancer Research.
According to data from OpenAlex, Martin H. Voss has authored 219 papers receiving a total of 6.1k indexed citations (citations by other indexed papers that have themselves been cited), including 184 papers in Pulmonary and Respiratory Medicine, 95 papers in Molecular Biology and 84 papers in Cancer Research. Recurrent topics in Martin H. Voss's work include Renal cell carcinoma treatment (173 papers), Renal and related cancers (76 papers) and Cancer Genomics and Diagnostics (73 papers). Martin H. Voss is often cited by papers focused on Renal cell carcinoma treatment (173 papers), Renal and related cancers (76 papers) and Cancer Genomics and Diagnostics (73 papers). Martin H. Voss collaborates with scholars based in United States, Canada and Spain. Martin H. Voss's co-authors include Robert J. Motzer, A. Ari Hakimi, Ritesh R. Kotecha, James J. Hsieh, Brian I. Rini, David F. McDermott, Ying‐Bei Chen, Lynda Vuong, Paul Russo and Hans J. Hammers and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Martin H. Voss
206 papers receiving 6.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Martin H. Voss United States | 40 | 4.0k | 3.1k | 2.6k | 2.0k | 906 | 219 | 6.1k | ||
| Laura S. Wood United States | 29 | 3.1k 0.8× | 2.2k 0.7× | 2.3k 0.9× | 1.4k 0.7× | 525 0.6× | 99 | 4.9k | ||
| Frede Donskov Denmark | 45 | 5.7k 1.4× | 3.3k 1.1× | 4.2k 1.6× | 2.4k 1.2× | 1.3k 1.5× | 233 | 8.4k | ||
| Michael Siebels Germany | 22 | 3.4k 0.9× | 2.7k 0.9× | 1.6k 0.6× | 1.6k 0.8× | 626 0.7× | 65 | 5.2k | ||
| Manuel Cobo Spain | 30 | 3.4k 0.9× | 1.3k 0.4× | 3.6k 1.4× | 1.1k 0.5× | 349 0.4× | 219 | 5.3k | ||
| Khédoudja Nafa United States | 41 | 3.0k 0.8× | 2.3k 0.8× | 3.0k 1.2× | 1.9k 0.9× | 557 0.6× | 93 | 7.6k | ||
| В. А. Горбунова Russia | 24 | 5.5k 1.4× | 2.3k 0.7× | 4.5k 1.7× | 1.4k 0.7× | 956 1.1× | 61 | 7.2k | ||
| Talia Golan Israel | 39 | 1.7k 0.4× | 2.0k 0.7× | 5.4k 2.1× | 2.3k 1.1× | 975 1.1× | 170 | 7.2k | ||
| Ihor Vynnychenko Ukraine | 21 | 4.3k 1.1× | 1.4k 0.5× | 4.6k 1.8× | 901 0.4× | 1.4k 1.5× | 57 | 7.0k | ||
| Juliann Chmielecki United States | 40 | 4.1k 1.0× | 2.8k 0.9× | 3.6k 1.4× | 1.8k 0.9× | 571 0.6× | 116 | 7.2k | ||
| Naoyuki Nogami Japan | 30 | 5.4k 1.3× | 1.4k 0.5× | 5.9k 2.3× | 969 0.5× | 398 0.4× | 149 | 7.4k |
Countries citing papers authored by Martin H. Voss
Since
Specialization
Citations
This map shows the geographic impact of Martin H. Voss's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin H. Voss with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin H. Voss more than expected).
Fields of papers citing papers by Martin H. Voss
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Martin H. Voss. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin H. Voss. The network helps show where Martin H. Voss may publish in the future.
Co-authorship network of co-authors of Martin H. Voss
This figure shows the co-authorship network connecting the top 25 collaborators of Martin H. Voss. A scholar is included among the top collaborators of Martin H. Voss based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin H. Voss. Martin H. Voss is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Gouda, Mohamed A., Martin H. Voss, Hussein A. Tawbi, et al.. (2025). A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer. ESMO Open. 10(5). 104536–104536.
2.
Fitzgerald, Kelly N., Chung‐Han Lee, Martin H. Voss, et al.. (2024). Cabozantinib Plus Nivolumab in Patients with Non–Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. European Urology. 86(2). 90–94.
3.
Dizman, Nazlı, Andrea Knežević, Reza Alaghehbandan, et al.. (2024). A multi-institution analysis of outcomes with first-line systemic therapy for 99 patients with metastatic chromophobe renal cell carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 4512–4512.
4.
Guercio, Brendan J., Min Yuen Teo, Ashley Marie Regazzi, et al.. (2024). Associations of dietary fructose with survival of patients (pts) with metastatic cancer of the urothelium (UC) and renal cell carcinoma (RCC) on immune checkpoint blockade (ICB).. Journal of Clinical Oncology. 42(16_suppl). 4571–4571.
5.
Shah, Neal, Matthew T. Campbell, Shifeng Mao, et al.. (2023). 1889P Phase Ib/II study of batiraxcept (BT, AVB-S6-500, an AXL pathway inhibitor) in combination with cabozantinib (cabo) in patients with advanced clear cell renal cell carcinoma (ccRCC) who failed first-line (1L) therapy. Annals of Oncology. 34. S1016–S1017.
6.
Kotecha, Ritesh R., Andrea Knežević, Kanika Arora, et al.. (2023). Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer. 130(5). 692–701.
7.
Bilen, Mehmet Asım, Brian I. Rini, Martin H. Voss, et al.. (2021). Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial. Clinical Cancer Research. 28(4). 738–747.
8.
Beattie, Jason, Hira Rizvi, Jia Luo, et al.. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 9(2). e001884–e001884.
9.
Adib, Elio, Katarzyna Klonowska, Krinio Giannikou, et al.. (2021). Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway Alterations. Clinical Cancer Research. 27(14). 3845–3853.
10.
Feldman, Darren R., Yasser Ged, Chung‐Han Lee, et al.. (2020). Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial. Cancer. 126(24). 5247–5255.
11.
Voss, Martin H., Cinta Hierro, Rebecca S. Heist, et al.. (2019). A Phase I, Open-Label, Multicenter, Dose-escalation Study of the Oral Selective FGFR Inhibitor Debio 1347 in Patients with Advanced Solid Tumors Harboring FGFR Gene Alterations. Clinical Cancer Research. 25(9). 2699–2707.
12.
Hakimi, A. Ari, Martin H. Voss, Fengshen Kuo, et al.. (2019). Transcriptomic Profiling of the Tumor Microenvironment Reveals Distinct Subgroups of Clear Cell Renal Cell Cancer: Data from a Randomized Phase III Trial. Cancer Discovery. 9(4). 510–525.
13.
Harding, James J., Andrew X. Zhu, Todd M. Bauer, et al.. (2019). A Phase Ib/II Study of Ramucirumab in Combination with Emibetuzumab in Patients with Advanced Cancer. Clinical Cancer Research. 25(17). 5202–5211.
14.
Sánchez, Alejandro, Helena Furberg, Fengshen Kuo, et al.. (2019). Transcriptomic signatures related to the obesity paradox in patients with clear cell renal cell carcinoma: a cohort study. The Lancet Oncology. 21(2). 283–293.
15.
Lattanzi, Michael, Fang‐Ming Deng, Luis Chiriboga, et al.. (2018). Durable response to anti-PD-1 immunotherapy in epithelioid angiomyolipoma: a report on the successful treatment of a rare malignancy. Journal for ImmunoTherapy of Cancer. 6(1). 97–97.
16.
Hammers, Hans J., Elizabeth R. Plimack, Jeffrey R. Infante, et al.. (2017). Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study. Journal of Clinical Oncology. 35(34). 3851–3858.
17.
Voss, Martin H., Rupal S. Bhatt, Elizabeth R. Plimack, et al.. (2016). The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma. Clinical Cancer Research. 23(14). 3557–3565.
18.
Voss, Martin H., A. Ari Hakimi, Can G. Pham, et al.. (2014). Tumor Genetic Analyses of Patients with Metastatic Renal Cell Carcinoma and Extended Benefit from mTOR Inhibitor Therapy. Clinical Cancer Research. 20(7). 1955–1964.
19.
Bastos, Diogo Assed, Ana M. Molina, Vaios Hatzoglou, et al.. (2014). Safety and Efficacy of Targeted Therapy for Renal Cell Carcinoma With Brain Metastasis. Clinical Genitourinary Cancer. 13(1). 59–66.
20.
Hakimi, A. Ari, Irina Ostrovnaya, Boris Reva, et al.. (2013). Adverse Outcomes in Clear Cell Renal Cell Carcinoma with Mutations of 3p21 Epigenetic Regulators BAP1 and SETD2 : A Report by MSKCC and the KIRC TCGA Research Network. Clinical Cancer Research. 19(12). 3259–3267.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Laura S. Wood Breakdown of academic impact, for papers by Frede Donskov Breakdown of academic impact, for papers by Michael Siebels Breakdown of academic impact, for papers by Manuel Cobo Breakdown of academic impact, for papers by Khédoudja Nafa Breakdown of academic impact, for papers by В. А. Горбунова Breakdown of academic impact, for papers by Talia Golan Breakdown of academic impact, for papers by Ihor Vynnychenko Breakdown of academic impact, for papers by Juliann Chmielecki Breakdown of academic impact, for papers by Naoyuki Nogami